FDA Logo, hands holding pills

Viberzi (eluxadoline) Safety Podcast

FDA review shows increased risk of serious pancreatitis in patients without a gallbladder

  • Prescribed to treat irritable bowel syndrome with diarrhea (IBS-D)
  • Patients, without a gallbladder, have increased risk of developing serious pancreatitis that could result in hospitalization or death
  • Pancreatitis caused by spasm of certain digestive system muscle in the small intestine
  • FDA working with manufacturer, Allergan, to address safety concerns

LISTEN & LEARN


 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s